
  
    
      
        Background_NNP
        Glucocorticoids_NNP (_( GC_NNP 's_POS )_) are_VBP the_DT effectors_NNS of_IN stress_NN and_CC
        necessarily_RB impact_VB multiple_JJ target_NN tissues_NNS during_IN normal_JJ
        function_NN ._. Regulation_NNP of_IN GC_NNP levels_NNS occurs_VBZ through_IN the_DT
        hypothalamo-pituitary-adrenal_JJ axis_NNS (_( HPA_NNP )_) ._. Recent_JJ evidence_NN
        indicates_VBZ that_IN the_DT cytokine_NN ,_, leukemia_NN inhibitory_NN factor_NN
        (_( LIF_NNP )_) and_CC its_PRP$ functional_JJ binding_VBG to_TO the_DT high_JJ affinity_NN
        receptor_NN ,_, a_DT heterodimer_NN between_IN low-affinity_JJ LIFR_NNP and_CC
        glycoprotein_NN 130_CD (_( LIFR_NNP :_: gp_NN 130_CD )_) ,_, are_VBP players_NNS within_IN the_DT HPA_NNP
        cascade_NN of_IN events_NNS ._. The_DT ligands_NNS ciliary_JJ neurotrophic_JJ factor_NN
        (_( CNTF_NNP )_) ,_, cardiotrophin-_NN 1_CD (_( CT-_NNP 1_LS )_) and_CC a_DT novel_NN neurotrophin_NN
        set_VBD ,_, known_VBN alternatively_RB as_IN NNT-_NNP 1_CD /_NN BSF_NNP 3_CD and_CC CLF_NNP /_NN CLC_NNP ,_, also_RB
        function_NN through_IN the_DT high_JJ affinity_NN LIFR_NNP :_: gp_NN 130_CD heterodimeric_JJ
        receptor_NN but_CC require_VB a_DT third_JJ ligand-binding_JJ but_CC
        non-signaling_JJ subunit_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._. Oncostatin_NNP M_NNP (_( OSM_NNP )_)
        utilizes_NNS LIFR_NNP :_: gp_NN 130_CD as_IN an_DT alternative_JJ receptor_NN complex_JJ for_IN
        OSM_NNP signaling_VBG in_IN humans_NNS [_NN 5_CD ]_NN ,_, but_CC not_RB in_IN mice_NNS [_NN 6_CD ]_NN ._.
        Thus_RB ,_, in_IN mice_NNS LIFR_NNP :_: gp_NN 130_CD is_VBZ obligatory_JJ for_IN signaling_VBG
        induced_VBN by_IN LIF_NNP ,_, CNTF_NNP ,_, CT-_NNP 1_CD and_CC CLF_NNP /_NN CLC_NNP ._. Signaling_NNP proceeds_NNS
        through_IN the_DT Janus_NNP kinase_NN /_NN signal_NN transducers_NNS and_CC activators_NNS
        of_IN transcription_NN (_( JAK_NNP /_NN STAT_NNP )_) or_CC the_DT ras-mitogen-activated_JJ
        protein_NN (_( MAP_NNP )_) kinase_NN pathways_NNS [_NN for_IN a_DT review_NN see_VB [_NN 7_CD ]_NN
        ]_NN ._.
        LIF_NNP and_CC LIFR_NNP are_VBP functionally_RB expressed_VBN in_IN rodent_NN
        tissues_NNS that_WDT are_VBP central_JJ to_TO GC_NNP production_NN :_: the_DT hypothalamus_JJ
        [_NN 8_CD ]_NN and_CC pituitary_JJ [_NN 9_CD 10_CD 11_CD 12_CD ]_NN ._. LIF_NNP works_VBZ in_IN synergy_NN
        with_IN corticotropin-releasing_JJ hormone_NN (_( CRH_NNP )_) in_IN the_DT
        hypothalamus_JJ to_TO increase_VB pituitary_JJ pro-opiomelanocortin_JJ
        (_( POMC_NNP )_) and_CC ,_, ultimately_RB ,_, pituitary_JJ adrenocorticotrophin_NN
        hormone_NN (_( ACTH_NNP )_) [_NN 9_CD 11_CD 13_CD 14_CD 15_CD 16_CD ]_NN ._. LIF_NNP also_RB stimulates_NNS
        POMC_NNP gene_NN expression_NN directly_RB in_IN the_DT pituitary_JJ [_NN 9_CD 11_CD 15_CD 17_CD
        ]_NN ._. LIF_NNP up-regulates_JJ pituitary_JJ prohormone_NN convertase_NN (_( PC_NN 1_LS )_) ._.
        Subsequently_RB ,_, PC_NN 1_CD goes_VBZ on_IN to_TO facilitate_VB POMC_NNP processing_NN to_TO
        ACTH_NNP [_NN 18_CD ]_NN within_IN the_DT pituitary_JJ ._. LIF_NNP promotes_VBZ survival_NN of_IN
        magnocellular_NN vasopressinergic_JJ neurons_NNS in_IN the_DT hypothalamus_JJ
        [_NN 19_CD ]_NN which_WDT ultimately_RB also_RB positively_RB influences_VBZ ACTH_NNP
        level_NN ._. Thus_RB ,_, it_PRP is_VBZ well_RB documented_VBN in_IN rodents_NNS that_IN
        signaling_VBG through_IN the_DT LIFR_NNP :_: gp_NN 130_CD heterodimer_NN in_IN the_DT
        hypothalamus_JJ and_CC pituitary_JJ leads_VBZ to_TO adrenal_NN GC_NNP production_NN
        via_IN elevated_VBD ACTH_NNP ._. Other_JJ LIF_NNP effects_NNS that_WDT may_MD influence_VB the_DT
        stress_NN response_NN through_IN actions_NNS in_IN the_DT rodent_NN nervous_JJ
        system_NN are_VBP a_DT LIF_NNP induced_VBN increase_NN in_IN acetylcholine_NN [_NN 20_CD ]_NN
        and_CC LIF_NNP induced_VBD decreases_NNS in_IN neuropeptide_NN Y_NNP and_CC tyrosine_NN
        hydroxylase_NN [_NN 21_CD ]_NN ._. LIFR_NNP :_: gp_NN 130_CD signaling_VBG has_VBZ strong_JJ
        effects_NNS in_IN systems_NNS peripheral_JJ to_TO but_CC influenced_VBN by_IN the_DT HPA_NNP
        including_VBG reproductive_JJ ,_, skeletal_NN ,_, nervous_JJ ,_, neuromuscular_NN ,_,
        cardiovascular_JJ ,_, hematopoietic_JJ ,_, immune_JJ and_CC metabolic_JJ
        systems_NNS ,_, with_IN influences_VBZ on_IN both_DT development_NN and_CC adult_NN
        homeostasis_NNS [_NN for_IN reviews_NNS see_VBP [_NN 7_CD 22_CD 23_CD 24_CD 25_CD 26_CD 27_CD ]_NN ]_NN ._.
        Animal_NNP models_NNS of_IN LIF_NNP over_IN expression_NN and_CC ablation_NN have_VBP
        confirmed_VBN importance_NN in_IN stress_NN regulation_NN ._. Adult_NNP mouse_NN LIF_NNP
        over_IN expression_NN mediated_JJ by_IN transfer_NN of_IN LIF_NNP over_IN expressing_VBG
        hematopoietic_JJ cells_NNS results_NNS in_IN a_DT lethal_JJ ,_, multi-systemic_JJ
        phenotype_NN that_WDT includes_VBZ small_JJ adrenals_NNS with_IN a_DT loss_NN of_IN the_DT
        innermost_NN cortical_JJ layer_NN [_NN 28_CD ]_NN ._. Pituitary_NNP specific_JJ LIF_NNP
        over_IN expression_NN leads_VBZ to_TO a_DT Cushing_NNP 's_POS Syndrome-like_NNP
        condition_NN of_IN GC_NNP hyperactivity_NN [_NN 29_CD 30_CD ]_NN ._. LIF_NNP null_NN adult_NN
        mice_NNS have_VBP normal_JJ or_CC slightly_RB reduced_VBN basal_NN ACTH_NNP and_CC GC_NNP
        concentrations_NNS ,_, and_CC are_VBP unable_JJ to_TO respond_VB to_TO acute_JJ stress_NN
        by_IN increased_VBN ACTH_NNP ._. Basal_NNP POMC_NNP is_VBZ reduced_VBN ,_, but_CC inducible_JJ
        upon_IN stress_NN [_NN 16_CD ]_NN ._. Thus_RB ,_, an_DT obligatory_JJ function_NN of_IN LIF_NNP
        may_MD be_VB in_IN the_DT processing_NN of_IN POMC_NNP to_TO ACTH_NNP during_IN acute_JJ
        stress_NN ._.
        Null_NNP mutation_NN of_IN LIFR_NNP results_NNS in_IN neonatal_NN death_NN and_CC
        defects_NNS in_IN many_JJ systems_NNS including_VBG absence_NN of_IN glial_NN cells_NNS ,_,
        osteoporosis_NNS ,_, glycogen_NN hyper-synthesis_JJ ,_, placental_NN defects_NNS [_NN
        31_CD ]_NN and_CC loss_NN of_IN motor_NN neuronal_NN subsets_NNS that_WDT cripple_NN
        suckling_VBG ability_NN [_NN 32_CD ]_NN ._. In_IN all_DT of_IN the_DT systems_NNS affected_VBN as_IN
        a_DT biological_JJ consequence_NN of_IN LIFR_NNP loss_NN ,_, an_DT explanation_NN of_IN
        the_DT mechanism_NN of_IN action_NN can_MD be_VB designed_VBN around_IN direct_JJ
        action_NN of_IN LIFR_NNP in_IN each_DT system_NN ._. However_RB ,_, when_WRB considered_VBN as_IN
        a_DT whole_JJ ,_, direct_JJ ,_, non-redundant_JJ obligatory_JJ LIFR_NNP function_NN in_IN
        such_JJ diverse_JJ systems_NNS makes_VBZ little_RB evolutionary_JJ sense_NN ._. LIFR_NNP
        function_NN within_IN the_DT stress_NN response_NN system_NN could_MD be_VB a_DT
        unifying_JJ element_NN in_IN many_JJ of_IN the_DT diverse_JJ biological_JJ
        consequences_NNS of_IN LIFR_NNP loss_NN ._. Among_IN the_DT defects_NNS seen_VBN upon_IN
        developmental_NN LIFR_NNP loss_NN ,_, all_DT but_CC the_DT loss_NN of_IN suckling_VBG
        ability_NN and_CC placental_NN changes_NNS mirror_VBP reported_VBN effects_NNS of_IN GC_NNP
        excess_JJ in_IN the_DT adult_NN ._. This_DT study_NN explores_VBZ the_DT effect_NN of_IN
        alteration_NN of_IN the_DT GC_NNP environment_NN during_IN late_JJ gestation_NN ,_,
        with_IN the_DT expectation_NN that_DT suppression_NN of_IN GC_NNP effects_NNS will_MD
        improve_VB the_DT LIFR_NNP null_NN newborn_JJ phenotype_NN and_CC identify_VB LIFR_NNP
        as_IN an_DT obligatory_JJ player_NN in_IN concert_NN with_IN the_DT maternal_NN GC_NNP
        surge_NN during_IN late_JJ gestation_NN development_NN ._. To_TO link_VB LIFR_NNP
        function_NN with_IN GC_NNP function_NN we_PRP have_VBP manipulated_VBN the_DT late_JJ
        gestation_NN maternal_NN steroid_NN profile_NN by_IN maternal_NN
        adrenalectomy_NN or_CC RU_NNP 486_CD administration_NN to_TO determine_VB if_IN the_DT
        maternal_NN GC_NNP surge_NN impacts_NNS fetal_JJ well_RB being_VBG in_IN the_DT absence_NN
        of_IN LIFR_NNP and_CC functional_JJ LIFR_NNP :_: gp_NN 130_CD signaling_VBG ._. RU_NNP 486_CD
        administration_NN during_IN late_JJ gestation_NN results_NNS in_IN improved_VBN
        development_NN of_IN bone_NN ,_, skeletal_NN muscle_NN ,_, and_CC glial_NN cells_NNS in_IN
        LIFR_NNP null_NN fetuses_NNS ._.
      
      
        Methods_NNP
        
          Mice_NNS
          The_DT mice_NNS used_VBN in_IN this_DT study_NN were_VBD first_RB described_VBD in_IN
          1995_CD [_NN 31_CD ]_NN ._. Disruption_NNP of_IN the_DT first_JJ coding_VBG exon_NN with_IN a_DT
          promterless_JJ Î²-galactosidase_JJ /_NN neomycin_NN resistance_NN fusion_NN
          cassette_NN [_NN 33_CD ]_NN created_VBD a_DT null_NN allele_NN for_IN 
          Lifr_NNP ._. AB_NNP 1_CD ES_NNP cells_NNS ,_, on_IN
          a_DT 129_CD S_NNP 7_CD /_NN SvEvBrd-_NNP 
          Hprt_NNP 
          b_SYM -_: 
          m_NN 2_CD background_NN ,_, were_VBD used_VBN for_IN
          targeting_VBG 
          Lifr_NNP ._. The_DT mice_NNS were_VBD sent_VBN to_TO the_DT
          Induced_NNP Mutant_NNP Resource_NNP of_IN the_DT Jackson_NNP Laboratory_NNP in_IN
          1994_CD ,_, from_IN where_WRB one_CD heterozygous_JJ (_( 
          Lifr_NNP +_NN /_NN -_: )_) male_NN was_VBD received_VBN in_IN 1997_CD
          to_TO re-establish_VB the_DT colony_NN at_IN the_DT University_NNP of_IN
          Washington_NNP ._. Since_IN the_DT initial_JJ germ_NN line_NN chimera_NN ,_, the_DT line_NN
          has_VBZ been_VBN bred_VBN back_RB to_TO C_NNP 57_CD BL_NNP /_NN 6_CD for_IN over_IN 5_CD generations_NNS and_CC
          there_EX have_VBP been_VBN several_JJ generations_NNS of_IN sibling_VBG matings_NNS ._.
          Thus_RB ,_, although_IN exact_JJ records_NNS were_VBD not_RB kept_VBN ,_, the_DT mice_NNS are_VBP
          on_IN a_DT predominantly_RB C_NNP 57_CD BL_NNP /_NN 6_CD background_NN (_( >_NN 96_CD %_NN )_) ._. All_DT work_NN
          was_VBD carried_VBN out_IN following_VBG the_DT Institutional_NNP Animal_NNP Care_NNP
          and_CC Use_NNP Committee_NNP guidelines_NNS within_IN an_DT Association_NNP for_IN
          Assessment_NNP and_CC Accreditation_NNP of_IN Laboratory_NNP Animal_NNP Care_NNP
          approved_VBD specific_JJ pathogen-free_JJ facility_NN ._.
          
          Lifr_NNP +_NN /_NN -_: females_NNS were_VBD mated_VBN to_TO 
          Lifr_NNP +_NN /_NN -_: males_NNS and_CC the_DT day_NN of_IN plug_NN
          (_( E_NNP 0_CD ._. 5_LS )_) recorded_VBN ._. Pups_NNP were_VBD either_CC born_VBN naturally_RB or_CC
          derived_VBN by_IN Cesarean_NNP section_NN (_( C-_NNP section_NN )_) on_IN E_NNP 18_CD ._. 5_LS as_IN
          described_VBN [_NN 34_CD ]_NN ._. The_DT E_NNP 18_CD ._. 5_LS pups_NNS were_VBD placed_VBN in_IN a_DT dish_NN
          on_IN ice_NN to_TO induce_VB hypothermia_NN and_CC sleep_VB followed_VBN by_IN
          euthanasia_NN through_IN decapitation_NN ._. Tail_NNP snips_NNS were_VBD used_VBN for_IN
          genotyping_VBG by_IN polymerase_NN chain_NN reaction_NN as_RB previously_RB
          described_VBD [_NN 31_CD ]_NN ._.
        
        
          Hormone_NNP manipulation_NN
          E_NNP 16_CD ._. 5_LS was_VBD chosen_VBN as_IN the_DT starting_NN point_NN for_IN each_DT
          treatment_NN since_IN no_DT phenotypic_JJ differences_NNS among_IN the_DT 
          Lifr_NNP genotypes_NNS was_VBD detected_VBN at_IN this_DT
          point_NN ._. Noticeable_NNP differences_NNS were_VBD seen_VBN beginning_VBG on_IN
          E_NNP 17_CD ._. 5_LS [_NN 31_CD ]_NN ._. Also_RB ,_, fetal_JJ feedback_NN control_NN of_IN GC_NNP
          production_NN is_VBZ established_VBN on_IN E_NNP 16_CD ._. 5_LS coincident_JJ with_IN the_DT
          initiation_NN of_IN the_DT maternal_NN surge_NN [_NN 35_CD ]_NN ._. Adrenalectomy_NNP
          of_IN E_NNP 16_CD ._. 5_LS pregnant_JJ mice_NNS was_VBD performed_VBN as_RB previously_RB
          described_VBD [_NN 36_CD ]_NN ._. Briefly_NNP ,_, adult_NN mice_NNS were_VBD anesthetized_JJ
          using_VBG ketamine_NN and_CC xylazine_NN ._. The_DT site_NN was_VBD prepped_JJ and_CC a_DT
          small_JJ incision_NN (_( ~_NN 1_CD cm_NN )_) made_VBN on_IN the_DT right_JJ side_NN of_IN the_DT
          spine_NN over_IN the_DT upper_JJ kidney_NN ._. The_DT adrenal_NN gland_NN was_VBD
          located_VBN and_CC excised_VBN ,_, with_IN care_NN taken_VBN to_TO avoid_VB damage_NN of_IN
          blood_NN vessels_NNS ._. Following_VBG removal_NN of_IN the_DT right_JJ adrenal_NN ,_,
          one_CD suture_NN was_VBD placed_VBN to_TO close_VB the_DT muscle_NN incision_NN ._. The_DT
          adrenalectomy_NN procedure_NN was_VBD repeated_VBN on_IN the_DT left_NN side_NN ._.
          The_DT skin_NN was_VBD closed_VBN using_VBG a_DT 9_CD mm_NN wound_VBD clip_VB ._. No_DT hormonal_NN
          support_NN was_VBD provided_VBN ._. Pups_NNP were_VBD born_VBN following_VBG C-_NNP section_NN
          on_IN E_NNP 18_CD ._. 5_LS ._. Two_CD litters_NNS containing_VBG in_IN total_JJ 3_CD 
          Lifr_NNP +_NN /_NN +_NN ,_, 6_CD 
          Lifr_NNP +_NN /_NN -_: and_CC 5_CD 
          Lifr_NNP -_: /_NN -_: pups_NNS were_VBD studied_VBN ._. Within_IN
          litter_NN 
          Lifr_NNP +_NN /_NN +_NN and_CC +_NN /_NN -_: pups_NNS served_VBD as_IN
          controls_NNS since_IN there_EX has_VBZ been_VBN no_DT detectable_JJ gene_NN dose_NN
          effect_NN between_IN 
          Lifr_NNP +_NN /_NN +_NN and_CC +_NN /_NN -_: at_IN this_DT stage_NN of_IN
          development_NN ._. No_DT mock_JJ surgeries_NNS were_VBD performed_VBN ._.
          Lyophilized_NNP RU_NNP 486_CD (_( National_NNP Hormone_NNP and_CC Peptide_NNP
          Program_NNP )_) was_VBD dissolved_VBN to_TO 20_CD mg_NN /_NN ml_NN in_IN ethanol_NN and_CC diluted_VBN
          to_TO 25_CD Î¼g_NN /_NN ml_NN in_IN peanut_NN oil_NN ._. RU_NNP 486_CD was_VBD administered_VBN as_IN a_DT
          subcutaneous_JJ injection_NN of_IN 2_CD ._. 5_CD Î¼g_NN /_NN mouse_NN in_IN 0_CD ._. 1_CD ml_NN of_IN
          peanut_NN oil_NN on_IN E_NNP 16_CD ._. 5_LS and_CC E_NNP 17_CD ._. 5_LS ._. Pups_NNP were_VBD born_VBN by_IN natural_JJ
          delivery_NN on_IN E_NNP 18_CD ._. 5_LS ._. Three_CD litters_NNS containing_VBG in_IN total_JJ 5_CD 
          Lifr_NNP +_NN /_NN +_NN ,_, 10_CD 
          Lifr_NNP +_NN /_NN -_: and_CC 4_CD 
          Lifr_NNP -_: /_NN -_: pups_NNS were_VBD studied_VBN ._. These_DT
          were_VBD compared_VBN with_IN their_PRP$ littermates_NNS and_CC to_TO control_VB
          groups_NNS that_WDT experienced_VBD no_DT hormone_NN intervention_NN ._.
          C-_NNP section_NN delivery_NN of_IN untreated_JJ control_NN animals_NNS was_VBD
          performed_VBN on_IN E_NNP 18_CD ._. 5_LS ._. Three_CD untreated_JJ control_NN litters_NNS
          containing_VBG in_IN total_JJ 6_CD 
          Lifr_NNP +_NN /_NN +_NN ,_, 3_CD 
          Lifr_NNP +_NN /_NN -_: and_CC 7_CD 
          Lifr_NNP -_: /_NN -_: pups_NNS were_VBD studied_VBN ._.
          Comparisons_NNP were_VBD made_VBN between_IN 
          Lifr_NNP -_: /_NN -_: versus_CC 
          Lifr_NNP +_NN /_NN +_NN and_CC +_NN /_NN -_: littermate_NN
          controls_NNS ._.
        
        
          Histology_NNP
          E_NNP 18_CD ._. 5_LS fetuses_NNS were_VBD fixed_VBN in_IN 4_CD %_NN paraformaldehyde_NN in_IN PBS_NNP
          for_IN paraffin_NN sectioning_VBG ._. Paraffin_NNP blocks_NNS were_VBD cut_VBN in_IN 5_CD -_: 6_CD
          Î¼m_NN sections_NNS ,_, deparaffinized_JJ and_CC hydrated_JJ to_TO water_VB prior_RB
          to_TO staining_VBG ._. Sections_NNP were_VBD stained_JJ with_IN hematoxylin_NN and_CC
          eosin_NN (_( H_NNP &_CC E_NNP )_) or_CC by_IN periodic_JJ acid-_NN Schiff_NNP (_( PAS_NNP )_) ._. For_IN
          PAS_NNP ,_, slides_VBZ were_VBD placed_VBN in_IN 0_CD ._. 5_CD %_NN periodic_JJ acid_NN (_( Sigma_NNP )_) for_IN
          10_CD minutes_NNS ._. They_PRP were_VBD rinsed_JJ in_IN water_NN and_CC placed_VBN in_IN
          Schiff_NNP reagent_NN (_( Sigma_NNP )_) for_IN 30_CD minutes_NNS ,_, washed_VBN and_CC
          counterstained_JJ with_IN Gill_NNP 3_CD hematoxylin_NN (_( Sigma_NNP )_) ._. Slides_NNS
          treated_VBN with_IN diastase_NN to_TO digest_VB sugars_NNS were_VBD compared_VBN with_IN
          untreated_JJ slides_NNS to_TO control_VB for_IN specificity_NN of_IN PAS_NNP
          staining_VBG ._. Immunohistochemistry_NNP was_VBD performed_VBN using_VBG
          antibodies_NNS to_TO ACTH_NNP (_( rabbit_NN polyclonal_NN anti-_NN ACTH_NNP ;_: Chemicon_NNP
          International_NNP )_) or_CC glial_NN fibrillary_JJ acid_NN protein_NN (_( rabbit_NN
          polyclonal_NN anti-_NN GFAP_NNP ;_: Chemicon_NNP International_NNP )_) ._. Antibody_NNP
          binding_JJ was_VBD visualized_JJ using_VBG the_DT Universal_NNP Quick_NNP Kit_NNP with_IN
          NovaRed_NNP (_( Vector_NNP )_) ._.
          Skeletal_NNP preparations_NNS followed_VBD a_DT combination_NN of_IN the_DT
          protocols_NNS of_IN Gendron-_NNP Maguire_NNP et_CC al_NN ._. [_NN 37_CD ]_NN and_CC Rijli_NNP et_CC
          al_NN ._. [_NN 38_CD ]_NN ._. Briefly_NNP ,_, the_DT fetuses_NNS were_VBD eviscerated_JJ ,_, the_DT
          skin_NN was_VBD removed_VBN and_CC they_PRP were_VBD fixed_VBN in_IN 100_CD %_NN ethanol_NN for_IN
          four_CD days_NNS followed_VBN by_IN three_CD days_NNS in_IN acetone_NN ._. They_PRP were_VBD
          rinsed_JJ with_IN water_NN and_CC transferred_VBN to_TO staining_VBG solution_NN
          which_WDT contained_VBD 1_CD volume_NN of_IN 0_CD ._. 1_CD %_NN Alizarin_NNP red_JJ S_NNP (_( Sigma_NNP )_) ,_,
          1_CD volume_NN of_IN 3_CD %_NN alcian_NN blue_JJ (_( Sigma_NNP )_) ,_, 1_CD volume_NN acetic_JJ acid_NN
          and_CC 17_CD volumes_NNS ethanol_NN ._. After_IN staining_VBG for_IN 10_CD days_NNS ,_, the_DT
          skeletons_NNS were_VBD rinsed_JJ with_IN water_NN ,_, followed_VBN by_IN immersion_NN
          in_IN 20_CD %_NN glycerol_NN in_IN 1_CD %_NN potassium_NN hydroxide_NN overnight_JJ at_IN
          37_CD Â°_NN C_NNP and_CC held_VBN at_IN room_NN temperature_NN until_IN cleared_VBD ._. At_IN this_DT
          point_NN they_PRP were_VBD passed_VBN through_IN 50_CD ,_, 80_CD and_CC 100_CD %_NN glycerol_NN
          for_IN storage_NN ._.
          Only_RB within_IN litter_NN mice_NNS were_VBD compared_VBN ._. Following_VBG
          detection_NN of_IN differences_NNS ,_, an_DT array_NN of_IN slides_NNS and_CC tissues_NNS
          were_VBD presented_VBN to_TO a_DT pathologist_NN blinded_JJ to_TO genotype_NN for_IN
          confirmation_NN ._. The_DT numbers_NNS of_IN pups_NNS observed_VBD for_IN each_DT
          parameter_NN are_VBP listed_VBN in_IN Table_NNP 1_CD ._.
        
        
          Radio-immune_NNP assay_NN (_( RIA_NNP )_) for_IN corticosterone_NN
          Samples_NNP were_VBD run_VBN at_IN a_DT dilution_NN of_IN 1_CD :_: 200_CD using_VBG a_DT kit_NN
          (_( ICN_NNP )_) in_IN the_DT recommended_VBN diluent_NN using_VBG the_DT kit_NN protocol_NN ._.
          The_DT standards_NNS spanned_VBD 0_CD ._. 125_CD -_: 5_CD ._. 00_CD ng_NN /_NN ml_NN ._. All_DT samples_NNS were_VBD
          run_VBN in_IN the_DT same_JJ assay_NN with_IN high_JJ and_CC low_JJ controls_NNS ._.
          Samples_NNP ,_, standards_NNS and_CC controls_NNS were_VBD run_VBN in_IN duplicate_VB and_CC
          results_NNS averaged_VBD ._. Blanks_NNP were_VBD run_VBN in_IN quadruplicate_NN and_CC
          results_NNS averaged_VBD ._. The_DT standard_JJ curve_NN was_VBD calculated_VBN using_VBG
          a_DT four-parameter_JJ logistic_JJ curve_NN fit_NN ._. All_DT samples_NNS were_VBD
          between_IN 25_CD -_: 87_CD %_NN bound_VBN ._. The_DT coefficient_NN of_IN variance_NN between_IN
          duplicate_VB samples_NNS was_VBD 5_CD %_NN or_CC less_JJR for_IN all_DT samples_NNS ,_,
          standards_NNS and_CC controls_NNS ._.
        
      
      
        Results_NNS
        
          Consistent_NNP Phenotype_NNP
          The_DT phenotype_NN due_JJ to_TO LIFR_NNP loss_NN has_VBZ remained_VBN consistent_JJ
          throughout_IN the_DT transition_NN through_IN three_CD separate_JJ
          institutions_NNS and_CC between_IN the_DT transition_NN from_IN ,_,
          129_CD S_NNP 7_CD /_NN SvEvBrd-_NNP 
          Hprt_NNP 
          b_SYM -_: 
          m_NN 2_CD to_TO greater_JJR than_IN 96_CD %_NN C_NNP 57_CD BL_NNP /_NN 6_CD ._. In_IN
          particular_JJ ,_, LIFR_NNP null_NN mutation_NN remains_VBZ a_DT neonatal_NN lethal_JJ
          with_IN associated_VBN osteopenia_NN and_CC an_DT absence_NN of_IN glial_NN cells_NNS
          in_IN late_JJ gestation_NN ,_, as_IN described_VBN below_IN ._.
        
        
          Effect_NN of_IN Altered_NNP GC_NNP Action_NNP
          Two_CD approaches_NNS were_VBD used_VBN to_TO attempt_VB to_TO reduce_VB the_DT
          effects_NNS of_IN the_DT maternal_NN GC_NNP surge_NN on_IN the_DT fetus_NN ._. The_DT first_JJ
          approach_NN toward_IN manipulating_VBG the_DT maternal_NN GC_NNP surge_NN was_VBD
          maternal_NN adrenalectomy_NN on_IN E_NNP 16_CD ._. 5_LS ,_, without_IN further_JJ GC_NNP
          support_NN ._. Control_NNP 
          Lifr_NNP -_: /_NN -_: pups_NNS could_MD not_RB be_VB
          identified_VBN by_IN gross_JJ morphology_NN or_CC behavior_NN ._. 
          Lifr_NNP -_: /_NN -_: pups_NNS from_IN adrenalectomized_JJ
          mothers_NNS were_VBD noticeably_RB smaller_JJR than_IN the_DT littermates_NNS and_CC
          did_VBD not_RB move_VB vigorously_RB ._. The_DT gross_JJ morphology_NN and_CC
          behavior_NN could_MD accurately_RB identify_VB the_DT 4_CD 
          Lifr_NNP -_: /_NN -_: pups_NNS following_VBG treatment_NN
          that_IN presumably_RB heightened_VBD the_DT fetal_JJ exposure_NN to_TO GC_NNP 's_POS ._.
          Thus_RB ,_, the_DT impact_NN of_IN maternal_NN adrenalectomy_NN on_IN the_DT fetuses_NNS
          appeared_VBD to_TO have_VB a_DT selective_JJ negative_JJ effect_NN on_IN the_DT
          development_NN of_IN the_DT 
          Lifr_NNP -_: /_NN -_: pups_NNS ._.
          The_DT second_JJ approach_NN was_VBD to_TO administer_VB RU_NNP 486_CD on_IN E_NNP 16_CD ._. 5_LS
          and_CC E_NNP 17_CD ._. 5_LS to_TO block_VB the_DT effects_NNS of_IN the_DT GC_NNP surge_NN at_IN the_DT GR_NNP
          in_IN the_DT mother_NN and_CC in_IN the_DT fetus_NN ,_, following_VBG placental_NN
          transport_NN [_NN 39_CD ]_NN ._. We_PRP wanted_VBD to_TO find_VB a_DT dose_NN of_IN RU_NNP 486_CD that_WDT
          allowed_VBD litters_NNS to_TO be_VB born_VBN on_IN E_NNP 18_CD ._. 5_LS by_IN natural_JJ delivery_NN
          since_IN E_NNP 18_CD ._. 5_LS is_VBZ the_DT earliest_JJS day_NN of_IN natural_JJ birth_NN seen_VBN in_IN
          unmanipulated_JJ pregnancy_NN ._. A_DT dose_NN of_IN 5_CD -_: 10_CD Î¼g_NN per_IN mouse_NN
          generally_RB ,_, but_CC not_RB consistently_RB ,_, caused_VBN abortion_NN on_IN
          E_NNP 17_CD ._. 5_LS ._. Pups_NNP were_VBD born_VBN after_IN E_NNP 18_CD ._. 5_LS following_VBG a_DT dose_NN of_IN 1_CD ._. 0_CD
          Î¼g_NN RU_NNP 486_CD per_IN mouse_NN per_IN day_NN ._. A_DT 2_CD ._. 5_CD Î¼g_NN per_IN mouse_NN dose_NN
          induced_VBD birth_NN on_IN E_NNP 18_CD ._. 5_LS ._. However_RB ,_, response_NN throughout_IN was_VBD
          individual_JJ ._.
          A_DT pregnant_JJ mouse_NN was_VBD treated_VBN with_IN RU_NNP 486_CD on_IN E_NNP 16_CD ._. 5_LS and_CC
          17_CD ._. 5_LS ._. Following_VBG natural_JJ delivery_NN on_IN E_NNP 18_CD ._. 5_LS ,_, the_DT one_CD 
          Lifr_NNP -_: /_NN -_: pup_NN was_VBD indistinguishable_JJ
          from_IN the_DT littermates_NNS both_DT by_IN size_NN and_CC vigor_NN ,_, but_CC
          succumbed_VBD to_TO the_DT soporific_JJ effect_NN of_IN hypothermia_NN before_IN
          its_PRP$ littermates_NNS ._. Subsequently_RB ,_, a_DT further_JJ four_CD litters_NNS
          similarly_RB treated_VBN with_IN RU_NNP 486_CD were_VBD born_VBN by_IN natural_JJ
          delivery_NN and_CC left_VBN with_IN their_PRP$ mothers_NNS for_IN four_CD weeks_NNS ._. Of_IN
          the_DT 37_CD pups_NNS that_WDT survived_VBD to_TO weaning_VBG ,_, none_NN were_VBD 
          Lifr_NNP -_: /_NN -_: ._. No_DT pups_NNS were_VBD excluded_VBN
          from_IN the_DT litters_NNS on_IN the_DT day_NN of_IN birth_NN ;_: however_RB ,_, the_DT
          remains_NNS of_IN dead_JJ pups_NNS were_VBD found_VBN the_DT following_VBG day_NN ._. Only_RB
          one_CD pup_NN found_VBD dead_JJ on_IN the_DT day_NN after_IN birth_NN was_VBD of_IN
          sufficient_JJ quality_NN to_TO genotype_NN ,_, and_CC ,_, as_IN expected_VBN ,_, it_PRP was_VBD 
          Lifr_NNP -_: /_NN -_: ._. Two_CD more_JJR litters_NNS of_IN RU_NNP 486_CD
          treated_VBN pups_NNS were_VBD born_VBN by_IN natural_JJ delivery_NN on_IN E_NNP 18_CD ._. 5_LS ._.
          These_DT litters_NNS were_VBD taken_VBN on_IN E_NNP 18_CD ._. 5_LS for_IN analysis_NN ._. The_DT
          mothers_NNS accepted_VBD all_PDT the_DT pups_NNS into_IN the_DT litters_NNS ._. Four_CD pups_NNS
          had_VBD not_RB suckled_JJ ,_, as_IN evidenced_VBN by_IN the_DT lack_NN of_IN milk_NN in_IN
          their_PRP$ stomachs_NNS ,_, while_IN the_DT other_JJ 8_CD had_VBD ._. All_DT were_VBD otherwise_RB
          clinically_RB normal_JJ ._. Of_IN the_DT four_CD with_IN no_DT milk_NN ,_, three_CD
          succumbed_VBD to_TO hypothermia_NN more_RBR rapidly_RB than_IN the_DT rest_NN ._.
          These_DT three_CD proved_VBD to_TO be_VB 
          Lifr_NNP -_: /_NN -_: ._. The_DT one_CD additional_JJ pup_NN
          with_IN no_DT milk_NN in_IN its_PRP$ stomach_NN ,_, but_CC that_WDT resisted_VBD the_DT effect_NN
          of_IN hypothermia_NN the_DT longest_JJS of_IN the_DT four_CD was_VBD 
          Lifr_NNP +_NN /_NN -_: ._. All_DT the_DT littermates_NNS that_WDT
          had_VBD suckled_JJ and_CC had_VBD detectable_JJ milk_NN in_IN their_PRP$ stomachs_NNS
          were_VBD 
          Lifr_NNP +_NN /_NN +_NN (_( 2_CD pups_NNS )_) or_CC 
          Lifr_NNP +_NN /_NN -_: (_( 6_CD pups_NNS )_) ._. Consequently_RB ,_,
          RU_NNP 486_CD allowed_VBD the_DT 
          Lifr_NNP -_: /_NN -_: pups_NNS to_TO survive_VB natural_JJ
          delivery_NN and_CC maternal_NN culling_VBG ,_, although_IN they_PRP apparently_RB
          succumbed_VBD due_JJ to_TO an_DT inability_NN to_TO suckle_NN ._.
        
        
          Bone_NNP
          There_EX was_VBD no_DT loss_NN of_IN density_NN at_IN the_DT growth_NN plate_NN
          following_VBG any_DT of_IN the_DT treatments_NNS in_IN the_DT 
          Lifr_NNP +_NN /_NN +_NN and_CC +_NN /_NN -_: animals_NNS (_( Figure_NN
          1_CD A_DT ,_, 1_CD C_NNP ,_, 1_CD E_NNP )_) ._. The_DT expected_VBN loss_NN of_IN density_NN was_VBD seen_VBN at_IN the_DT
          growth_NN plate_NN in_IN the_DT untreated_JJ control_NN and_CC maternal_NN
          adrenalectomy_NN exposed_VBD 
          Lifr_NNP -_: /_NN -_: pups_NNS (_( Figure_NN 1_CD B_NNP ,_, 1_CD D_NNP )_) ._.
          Fragility_NNP may_MD be_VB increased_VBN in_IN the_DT adrenalectomy_NN group_NN as_IN
          evidenced_VBN by_IN broken_VBN mineralized_JJ bone_NN at_IN the_DT growth_NN plate_NN ,_,
          presumably_RB due_JJ to_TO osteopenia_NN combined_VBN with_IN handling_VBG post_NN
          mortem_NN ._. Of_IN the_DT 5_CD 
          Lifr_NNP -_: /_NN -_: pups_NNS from_IN pregnancies_NNS
          where_WRB the_DT mother_NN was_VBD adrenalectomized_JJ ,_, 4_CD had_VBD broken_VBN bones_NNS
          once_RB the_DT staining_VBG was_VBD complete_JJ ,_, whereas_IN ,_, no_DT stained_JJ bones_NNS
          from_IN the_DT 
          Lifr_NNP +_NN /_NN +_NN and_CC +_NN /_NN -_: littermates_NNS were_VBD
          broken_VBN ._. In_IN addition_NN ,_, all_DT bones_NNS from_IN both_DT control_NN and_CC
          RU_NNP 486_CD exposed_VBN litters_NNS remained_VBD intact_JJ throughout_IN the_DT
          staining_VBG process_NN ._. RU_NNP 486_CD treatment_NN of_IN the_DT mother_NN
          noticeably_RB protected_VBD 
          Lifr_NNP -_: /_NN -_: pups_NNS from_IN bone_NN loss_NN
          (_( Figure_NN 1_CD F_NN )_) ,_, although_IN modest_JJ thinning_VBG could_MD still_RB be_VB
          seen_VBN ,_, suggesting_VBG that_DT protection_NN was_VBD incomplete_JJ ._.
        
        
          Glial_NNP Cell_NNP Formation_NNP
          Consistent_NNP with_IN previous_JJ findings_NNS ,_, no_DT GFAP_NNP positive_JJ
          cells_NNS could_MD be_VB detected_VBN in_IN the_DT spinal_JJ cord_NN of_IN either_DT of_IN
          the_DT 
          Lifr_NNP -_: /_NN -_: untreated_JJ control_NN animals_NNS ._.
          Ordinarily_RB very_RB few_JJ GFAP_NNP positive_JJ cells_NNS are_VBP seen_VBN at_IN this_DT
          stage_NN of_IN development_NN in_IN wild_JJ type_NN animals_NNS ,_, making_VBG
          detection_NN of_IN GFAP_NNP positive_JJ cells_NNS dependent_JJ on_IN particular_JJ
          spinal_JJ cord_NN section_NN viewed_VBN ._. Seven_CD control_NN 
          Lifr_NNP +_NN /_NN +_NN ,_, 5_CD control_NN 
          Lifr_NNP -_: /_NN -_: ,_, 8_CD RU_NNP 486_CD exposed_VBN 
          Lifr_NNP +_NN /_NN +_NN and_CC +_NN /_NN -_: and_CC 11_CD RU_NNP 486_CD
          exposed_VBN 
          Lifr_NNP -_: /_NN -_: spinal_JJ cord_NN sections_NNS were_VBD
          immunolabeled_JJ ._. GFAP_NNP became_VBD detectable_JJ in_IN the_DT sections_NNS
          from_IN the_DT two_CD E_NNP 18_CD ._. 5_LS 
          Lifr_NNP -_: /_NN -_: animals_NNS analyzed_VBD when_WRB the_DT
          mother_NN was_VBD given_VBN RU_NNP 486_CD on_IN E_NNP 16_CD ._. 5_LS and_CC 17_CD ._. 5_LS of_IN gestation_NN
          (_( Figure_NN 2_LS )_) ._. Although_IN ,_, immunolabeling_VBG was_VBD reduced_VBN relative_JJ
          to_TO that_DT seen_VBN in_IN wild_JJ type_NN ._. GFAP_NNP immuno-positive_JJ cells_NNS
          were_VBD often_RB associated_VBN with_IN blood_NN vessels_NNS in_IN the_DT spinal_JJ
          cord_NN ._. Although_IN staining_VBG was_VBD relatively_RB spare_JJ in_IN all_DT
          sections_NNS ,_, complete_JJ absence_NN of_IN any_DT labeling_VBG near_IN vessels_NNS
          was_VBD apparent_JJ in_IN the_DT control_JJ 
          Lifr_NNP -_: /_NN -_: spinal_JJ cord_NN (_( Figure_NN
          2_CD B_NNP )_) ._.
        
        
          Skeletal_NNP Muscle_NNP
          Skeletal_NNP muscle_NN integrity_NN appeared_VBD compromised_VBN in_IN the_DT
          control_JJ 
          Lifr_NNP -_: /_NN -_: animals_NNS relative_JJ to_TO wild_JJ
          type_NN (_( Figure_NN 3_CD Aand_NNP 3_CD B_NNP )_) ._. This_DT was_VBD evidenced_VBN by_IN a_DT frayed_VBN ,_,
          granular_JJ appearance_NN with_IN loss_NN of_IN staining_VBG intensity_NN of_IN
          muscle_NN fibers_NNS in_IN 
          Lifr_NNP -_: /_NN -_: untreated_JJ controls_NNS ._. On_IN
          closer_JJR examination_NN ,_, the_DT individual_JJ muscle_NN fibers_NNS
          contained_VBD fine_NN vacuoles_NNS formed_VBN within_IN the_DT sarcoplasm_NN
          (_( Figure_NN 4_CD B_NNP ,_, arrows_NNS )_) ._. 
          Lifr_NNP -_: /_NN -_: pups_NNS treated_VBN with_IN RU_NNP 486_CD
          completely_RB lacked_VBD this_DT phenotype_NN and_CC appeared_VBD normal_JJ ._. The_DT
          characteristic_JJ appearance_NN of_IN skeletal_NN muscle_NN in_IN 
          Lifr_NNP -_: /_NN -_: mice_NNS may_MD be_VB due_JJ to_TO altered_VBN
          metabolism_NN as_IN evidenced_VBN by_IN glycogen_NN accumulation_NN ._. Modest_JJ ,_,
          but_CC inappropriate_JJ glycogen_NN accumulation_NN was_VBD also_RB seen_VBN in_IN 
          Lifr_NNP -_: /_NN -_: periodic_JJ acid-_NN Schiff_NNP
          stained_JJ skeletal_NN muscle_NN (_( Figure_NN 3_CD B_NNP )_) ._. Glycogen_NNP was_VBD barely_RB
          detectable_JJ in_IN comparable_JJ tissues_NNS from_IN 
          Lifr_NNP +_NN /_NN +_NN or_CC +_NN /_NN -_: littermates_NNS (_( Figure_NN
          3_CD A_DT )_) ._.
        
        
          Pituitary_NNP ACTH_NNP
          Immuno-staining_NNP for_IN ACTH_NNP in_IN the_DT pituitary_JJ showed_VBD no_DT
          profound_JJ difference_NN due_JJ to_TO LIFR_NNP loss_NN (_( Figure_NN 4_CD Aand_NNP 4_CD B_NNP )_) ._.
          Treatment_NNP with_IN RU_NNP 486_CD resulted_VBD in_IN apparent_JJ pituitary_JJ ACTH_NNP
          up-regulation_JJ as_IN evidenced_VBN by_IN increased_VBN immunolabeling_VBG
          regardless_RB of_IN genotype_NN (_( Figure_NN 4_CD Cand_NNP 4_CD D_NNP )_) ._. The_DT strongest_JJS
          ACTH_NNP immunolabeling_VBG was_VBD seen_VBN in_IN the_DT pars_NNS intermedia_NN of_IN
          the_DT anterior_NN pituitary_JJ with_IN scattered_VBN labeling_VBG in_IN the_DT
          pars_NNS distalis_NNS ._. This_DT was_VBD an_DT appropriate_JJ pattern_NN for_IN the_DT
          corticotroph_NN population_NN ._. Thus_RB ,_, the_DT corticotrophs_NNS did_VBD not_RB
          seem_VB altered_VBN by_IN LIFR_NNP loss_NN using_VBG this_DT method_NN of_IN
          assessment_NN ._. GC_NNP 's_POS induce_VB negative_JJ feedback_NN regulation_NN on_IN
          pituitary_JJ ACTH_NNP production_NN ,_, as_IN a_DT mechanism_NN for_IN protecting_VBG
          against_IN GC_NNP overproduction_NN ._. Because_IN RU_NNP 486_CD is_VBZ a_DT GR_NNP
          antagonist_NN ,_, it_PRP is_VBZ known_VBN that_DT administration_NN can_MD cause_VB
          increased_VBN pituitary_JJ ACTH_NNP production_NN [_NN 41_CD ]_NN ._. RU_NNP 486_CD
          exposure_NN increased_VBD pituitary_JJ ACTH_NNP levels_NNS in_IN both_DT the_DT 
          Lifr_NNP +_NN /_NN +_NN and_CC -_: /_NN -_: animals_NNS ,_, as_IN judged_VBN
          by_IN the_DT apparent_JJ increase_NN in_IN labeling_VBG density_NN through_IN
          immunohistochemistry_NN ._. Increased_VBN pituitary_JJ ACTH_NNP indicates_VBZ
          that_IN ,_, in_IN the_DT absence_NN of_IN LIFR_NNP ,_, pituitary_JJ ACTH_NNP could_MD still_RB
          be_VB induced_VBN ._. However_RB ,_, this_DT will_MD require_VB measurement_NN of_IN
          POMC_NNP by_IN quantitative_JJ methods_NNS ._.
        
        
          Lung_NNP
          Lung_NNP development_NN in_IN all_PDT the_DT pups_NNS looked_VBD normal_JJ as_IN
          viewed_VBN on_IN H_NNP &_CC E_NNP stained_JJ thin_JJ sections_NNS ._. The_DT lungs_NNS had_VBD
          inflated_VBN and_CC were_VBD indistinguishable_JJ between_IN treatments_NNS
          and_CC genotypes_NNS (_( Figure_NN 5_LS )_) ._.
        
        
          Serum_NNP Corticosterone_NNP
          Corticosterone_NNP levels_NNS in_IN blood_NN collected_VBN from_IN
          untreated_JJ control_NN pups_NNS or_CC pups_NNS from_IN pregnancies_NNS where_WRB the_DT
          mother_NN was_VBD adrenalectomized_JJ on_IN E_NNP 16_CD ._. 5_LS had_VBD no_DT evident_JJ
          correlation_NN to_TO 
          Lifr_NNP genotype_NN ,_, as_IN evidenced_VBN by_IN the_DT
          trial_NN results_NNS from_IN serum_NN collected_VBN from_IN only_RB a_DT few_JJ pups_NNS
          (_( Table_NNP 2_CD ._. )_) ._. Pups_NNP in_IN the_DT control_NN and_CC adrenalectomy_NN groups_NNS
          were_VBD born_VBN by_IN C-_NNP section_NN on_IN E_NNP 18_CD ._. 5_LS and_CC the_DT blood_NN collected_VBN
          within_IN one_CD hour_NN of_IN birth_NN ._. The_DT two_CD pups_NNS in_IN the_DT RU_NNP 486_CD group_NN
          were_VBD born_VBN by_IN natural_JJ delivery_NN and_CC were_VBD ex_FW utero_NN for_IN
          greater_JJR than_IN one_CD hour_NN prior_RB to_TO euthanasia_NN and_CC blood_NN
          collection_NN ._.
        
      
      
        Discussion_NNP
        The_DT results_NNS implicate_VB excess_JJ fetal_JJ GC_NNP response_NN in_IN late_JJ
        gestation_NN as_IN the_DT reason_NN for_IN the_DT multi-systemic_JJ phenotypes_NNS
        in_IN the_DT absence_NN of_IN LIFR_NNP ._. Maternal_NNP adrenalectomy_NN worsens_NNS the_DT
        osteopenia_NN ,_, while_IN maternal_NN hormone_NN suppression_NN through_IN
        RU_NNP 486_CD improves_VBZ the_DT presumed_VBN GC_NNP related_VBD phenotypes_NNS :_:
        osteopenia_NN ,_, skeletal_NN muscle_NN integrity_NN and_CC glial_NN
        development_NN ._. This_DT was_VBD an_DT improvement_NN over_IN the_DT poor_JJ
        prognosis_NN for_IN 
        Lifr_NNP -_: /_NN -_: newborns_NNS described_VBD initially_RB
        [_NN 31_CD ]_NN ._. In_IN that_DT study_NN ,_, 
        Lifr_NNP -_: /_NN -_: pups_NNS rarely_RB survived_VBD natural_JJ
        delivery_NN ,_, but_CC when_WRB they_PRP did_VBD ,_, they_PRP were_VBD excluded_VBN from_IN the_DT
        litter_NN and_CC died_VBD at_IN variable_JJ times_NNS beginning_VBG one_CD hour_NN
        following_VBG birth_NN ._. No_DT pups_NNS survived_VBD through_IN the_DT night_NN
        following_VBG birth_NN ._. The_DT survival_NN of_IN 
        Lifr_NNP -_: /_NN -_: pups_NNS following_VBG RU_NNP 486_CD
        treatment_NN was_VBD similar_JJ to_TO the_DT phenotype_NN seen_VBN in_IN CNTFR_NNP null_NN
        mice_NNS where_WRB neuronal_NN development_NN was_VBD disrupted_VBN which_WDT
        disallowed_VBD suckling_VBG [_NN 40_CD ]_NN ._. This_DT indicates_VBZ that_IN at_IN least_JJS
        some_DT of_IN the_DT problems_NNS encountered_VBD with_IN neuronal_NN development_NN
        that_WDT affect_VBP normal_JJ suckling_VBG were_VBD not_RB ameliorated_JJ by_IN RU_NNP 486_CD ._.
        Neither_DT adrenalectomy_NN nor_CC RU_NNP 486_CD treatment_NN impact_NN the_DT
        apparent_JJ well-being_NN of_IN the_DT 
        Lifr_NNP +_NN /_NN +_NN or_CC +_NN /_NN -_: littermates_NNS ._. Excess_NNP
        GC_NNP activity_NN due_JJ to_TO LIFR_NNP loss_NN is_VBZ an_DT unexpected_JJ result_NN since_IN
        LIF_NNP gain-of-function_JJ mice_NNS develop_VBP a_DT Cushing_NNP '_POS s-like_JJ syndrome_NN
        [_NN 29_CD 30_CD ]_NN ._. Thus_RB ,_, if_IN the_DT relationship_NN were_VBD simple_JJ ,_, loss_NN of_IN
        LIFR_NNP function_NN would_MD predict_VB development_NN of_IN GC_NNP
        insufficiency_NN ._. The_DT observed_VBD GC_NNP activity_NN excess_JJ suggests_VBZ
        that_IN LIF_NNP and_CC LIFR_NNP are_VBP integral_JJ to_TO GC_NNP regulation_NN ,_, but_CC that_IN
        the_DT relationship_NN is_VBZ complex_JJ and_CC that_IN alterations_NNS in_IN GC_NNP
        response_NN are_VBP likely_JJ to_TO result_VB from_IN altered_VBN balance_NN of_IN the_DT
        GC_NNP response_NN cascade_NN induced_VBD both_DT by_IN gain_NN and_CC loss_NN of_IN LIFR_NNP
        function_NN ._.
        There_EX is_VBZ a_DT maternal_NN GC_NNP surge_NN beginning_VBG on_IN E_NNP 16_CD ._. 5_LS ,_, where_WRB
        E_NNP 0_CD ._. 5_LS is_VBZ the_DT day_NN of_IN vaginal_JJ plug_NN following_VBG mating_NN ._. A_DT primary_JJ
        function_NN of_IN this_DT surge_NN is_VBZ to_TO allow_VB development_NN to_TO switch_VB
        from_IN growth_NN to_TO maturation_NN of_IN a_DT number_NN of_IN systems_NNS that_WDT will_MD
        allow_VB the_DT pup_NN to_TO survive_VB on_IN separation_NN from_IN the_DT mother_NN ._.
        Lung_NNP surfactant_NN synthesis_NN and_CC connective_JJ tissue_NN maturation_NN
        allow_VBP the_DT lungs_NNS to_TO become_VB distensible_JJ and_CC capable_JJ of_IN coping_VBG
        with_IN high_JJ surface_NN tension_NN ._. In_IN addition_NN ,_, the_DT maternal_NN GC_NNP
        surge_NN effectively_RB leads_VBZ to_TO fetal_JJ glycogen_NN accumulation_NN in_IN
        the_DT liver_NN for_IN energy_NN demands_NNS at_IN birth_NN ,_, increased_VBD fetal_JJ
        bioavailable_JJ tri-iodothyronine_JJ from_IN thyroxine_NN to_TO allow_VB for_IN
        an_DT increased_VBN metabolic_JJ rate_NN and_CC thermogenesis_NNS required_VBN at_IN
        birth_NN ,_, maturation_NN of_IN the_DT fetal_JJ small_JJ gut_NN to_TO prepare_VB for_IN
        digestion_NN ,_, heightened_VBD fetal_JJ adrenal_NN medullar_NN catecholamine_NN
        release_NN for_IN control_NN of_IN the_DT above_JJ processes_VBZ ,_, maturation_NN of_IN
        fetal_JJ kidney_NN function_NN and_CC a_DT switch_NN to_TO bone_NN marrow_NN
        hematopoiesis_NNS from_IN the_DT fetal_JJ liver_NN [_NN reviewed_VBN by_IN [_NN 41_CD ]_NN ]_NN ._.
        The_DT timing_NN of_IN this_DT maternal_NN surge_NN suggests_VBZ that_IN LIFR_NNP
        function_NN is_VBZ required_VBN at_IN this_DT point_NN in_IN development_NN as_IN a_DT
        moderator_NN of_IN the_DT consequences_NNS of_IN excess_JJ GC_NNP level_NN ._.
        Mock_NNP adrenal_NN surgeries_NNS were_VBD not_RB performed_VBN on_IN the_DT mice_NNS ._.
        Therefore_RB ,_, we_PRP do_VBP not_RB know_VB if_IN stress_NN of_IN surgery_NN alone_RB is_VBZ
        enough_RB to_TO impact_VB well-being_NN in_IN LIFR_NNP null_NN mice_NNS ._. Progesterone_NNP
        was_VBD administered_VBN in_IN peanut_NN oil_NN following_VBG the_DT same_JJ regimen_NN
        as_IN RU_NNP 486_CD ,_, but_CC resulted_VBD in_IN bone_NN loss_NN reminiscent_NN of_IN the_DT
        results_NNS following_VBG adrenalectomy_NN (_( unpublished_JJ observation_NN )_) ._.
        Thus_RB ,_, peanut_NN oil_NN alone_RB is_VBZ not_RB responsible_JJ for_IN the_DT
        improvements_NNS seen_VBN in_IN the_DT RU_NNP 486_CD group_NN and_CC the_DT effect_NN of_IN
        excess_JJ progesterone_NN provides_VBZ further_JJ evidence_NN that_IN the_DT LIFR_NNP
        phenotype_NN can_MD worsen_VB through_IN endocrine_NN manipulation_NN ._.
        We_PRP previously_RB reported_VBD that_DT placental_NN integrity_NN is_VBZ
        disrupted_VBN at_IN the_DT LIFR_NNP null_NN maternal-fetal_JJ interface_NN [_NN 31_CD ]_NN
        ._. In_IN that_DT study_NN ,_, the_DT maternal_NN response_NN to_TO disorganized_JJ
        fetal_JJ placental_NN tissue_NN was_VBD sufficient_JJ to_TO protect_VB the_DT fetus_NN
        from_IN malnutrition_NN ,_, since_IN there_EX was_VBD no_DT detectable_JJ disruption_NN
        of_IN fetal_JJ erythropoiesis_NNS ._. However_RB ,_, what_WP this_DT meant_VBN for_IN
        relative_JJ transport_NN of_IN RU_NNP 486_CD or_CC maternal_NN mediators_NNS of_IN fetal_JJ
        hormone_NN balance_NN upon_IN adrenalectomy_NN is_VBZ unknown_JJ ._. Maternal_NNP
        adrenalectomy_NN on_IN E_NNP 16_CD ._. 5_LS was_VBD a_DT naÃ¯ve_NN approach_NN toward_IN blocking_VBG
        the_DT maternal_NN GC_NNP surge_NN ._. It_PRP likely_RB had_VBD the_DT effect_NN of_IN
        increasing_VBG maternal_NN ACTH_NNP levels_NNS [_NN 42_CD ]_NN that_WDT would_MD ,_, in_IN turn_VB ,_,
        act_NN on_IN the_DT fetal_JJ adrenal_NN to_TO synthesize_VB corticosterone_NN ._. This_DT
        may_MD have_VB been_VBN the_DT source_NN of_IN the_DT modestly_RB elevated_VBD
        corticosterone_NN level_NN seen_VBN among_IN the_DT 
        Lifr_NNP null_NN pups_NNS in_IN the_DT adrenalectomy_NN
        group_NN ._. Although_IN anecdotal_JJ ,_, it_PRP would_MD appear_VB the_DT RU_NNP 486_CD
        exposed_VBN wildtype_NN animal_NN cleared_VBD residual_JJ late_JJ gestation_NN
        corticosterone_NN following_VBG birth_NN more_RBR effectively_RB than_IN did_VBD
        the_DT 
        Lifr_NNP -_: /_NN -_: littermate_NN ._. Previous_JJ studies_NNS
        measuring_VBG circulating_VBG insulin_NN and_CC glucose_NN levels_NNS in_IN
        C-_NNP section_NN derived_VBD E_NNP 18_CD ._. 5_LS pups_NNS bore_VBD no_DT apparent_JJ correlation_NN
        to_TO 
        Lifr_NNP genotype_NN (_( unpublished_JJ
        observation_NN )_) ._. At_IN the_DT time_NN it_PRP appeared_VBD that_IN plasma_NN
        measurements_NNS in_IN pups_NNS immediately_RB following_VBG C-_NNP section_NN were_VBD
        an_DT unreliable_JJ reflection_NN of_IN individual_JJ condition_NN and_CC were_VBD
        likely_JJ to_TO be_VB a_DT reflection_NN of_IN maternal_NN levels_NNS ._. An_DT accurate_JJ
        picture_NN of_IN corticosterone_NN levels_NNS will_MD probably_RB require_VB
        separation_NN from_IN the_DT mother_NN for_IN several_JJ hours_NNS ._.
        RU_NNP 486_CD was_VBD first_JJ explored_JJ as_IN a_DT GR_NNP antagonist_NN and_CC
        subsequently_RB found_VBD to_TO be_VB both_DT a_DT GR_NNP and_CC progesterone_NN
        receptor_NN (_( PR_NNP )_) antagonist_NN ,_, with_IN mild_JJ antagonistic_JJ effects_NNS on_IN
        the_DT androgen_NN receptor_NN ._. In_IN certain_JJ cases_NNS it_PRP can_MD function_VB as_IN
        a_DT mild_JJ agonist_NN ._. RU_NNP 486_CD can_MD bind_NN to_TO the_DT hormone-binding_JJ
        domain_NN of_IN both_DT GR_NNP and_CC PR_NNP ._. Although_IN still_RB able_JJ to_TO localize_NN
        to_TO the_DT nucleus_NN ,_, it_PRP prevents_VBZ subsequent_JJ transcription_NN of_IN GC_NNP
        and_CC progesterone_NN responsive_JJ genes_NNS ._. It_PRP does_VBZ not_RB directly_RB
        antagonize_VB the_DT mineralocorticoid_NN receptor_NN (_( MR_NNP )_) [_NN reviewed_VBN by_IN
        [_NN 43_CD ]_NN ]_NN ._.
        Because_IN RU_NNP 486_CD ,_, along_IN with_IN antagonizing_VBG the_DT GR_NNP
        antagonizes_NNS the_DT PR_NNP ,_, some_DT of_IN the_DT RU_NNP 486_CD benefit_NN may_MD be_VB due_JJ to_TO
        antagonism_NN of_IN progesterone_NN effects_NNS ._. Progesterone_NNP is_VBZ
        integral_JJ to_TO the_DT hormonal_NN milieu_NN ._. It_PRP is_VBZ processed_VBN to_TO GC_NNP 's_POS
        through_IN the_DT actions_NNS of_IN 21_CD hydroxylase_NN and_CC 11_CD Î²-hydroxylase_JJ
        [_NN 44_CD ]_NN and_CC it_PRP is_VBZ an_DT anti-_NN GC_NNP [_NN 45_CD 46_CD 47_CD 48_CD 49_CD ]_NN and_CC an_DT
        anti-mineralocorticoid_JJ (_( MC_NNP )_) [_NN 50_CD 51_CD 52_CD 53_CD ]_NN ._. Therefore_RB ,_, PR_NNP
        antagonism_NN by_IN RU_NNP 486_CD could_MD increase_VB GC_NNP and_CC MC_NNP effects_NNS ,_,
        although_IN this_DT is_VBZ the_DT opposite_NN of_IN the_DT phenotype_NN seen_VBN ._.
        Progesterone_NNP interacts_NNS synergistically_RB with_IN estrogen_NN in_IN
        bone_NN remodeling_VBG [_NN 54_CD ]_NN ,_, while_IN GC_NNP excess_NN is_VBZ implicated_VBN in_IN
        osteoporosis_NNS ._. LIFR_NNP is_VBZ known_VBN to_TO be_VB important_JJ in_IN the_DT balance_NN
        between_IN bone_NN resorption_NN and_CC bone_NN formation_NN acting_VBG directly_RB
        on_IN osteoblasts_NNS [_NN 55_CD 56_CD 57_CD ]_NN ._. Bone_NNP loss_NN in_IN the_DT untreated_JJ
        control_NN 
        Lifr_NNP -_: /_NN -_: pups_NNS suggests_VBZ a_DT heightened_VBN
        response_NN to_TO GC_NNP rather_RB than_IN a_DT heightened_VBN response_NN to_TO the_DT
        bone-remodeling_JJ effects_NNS of_IN progesterone_NN ._. Whereas_IN ,_,
        protection_NN by_IN RU_NNP 486_CD implies_VBZ antagonism_NN of_IN GR_NNP mediated_JJ bone_NN
        loss_NN ,_, rather_RB than_IN antagonism_NN of_IN PR_NNP mediated_JJ bone_NN
        remodeling_NN ._. In_IN addition_NN ,_, a_DT progesterone_NN receptor_NN knockout_NN
        mouse_NN model_NN affects_VBZ only_RB female_JJ mice_NNS with_IN reported_VBD effects_NNS
        limited_VBN to_TO organs_NNS of_IN reproduction_NN causing_VBG anovulation_NN ,_,
        uterine_NN hyperplasia_NN and_CC inflammation_NN ,_, limited_JJ mammary_JJ
        development_NN and_CC impaired_VBN sexual_JJ behavior_NN [_NN 58_CD ]_NN ._. There_EX was_VBD
        no_DT noticeable_JJ difference_NN in_IN phenotype_NN in_IN the_DT 
        Lifr_NNP -_: /_NN -_: pups_NNS due_JJ to_TO gender_VB following_VBG
        any_DT of_IN the_DT treatments_NNS (_( data_NNS not_RB shown_VBN )_) ._. Since_IN apparent_JJ
        defects_NNS due_JJ to_TO LIFR_NNP loss_NN arise_VB during_IN the_DT late_JJ gestation_NN GC_NNP
        surge_NN ,_, while_IN maternal_NN progesterone_NN levels_NNS are_VBP declining_VBG in_IN
        anticipation_NN of_IN birth_NN and_CC because_IN phenotypes_NNS that_WDT have_VBP been_VBN
        attributed_VBN in_IN the_DT literature_NN to_TO GC_NNP excess_JJ are_VBP lessened_JJ
        through_IN RU_NNP 486_CD and_CC the_DT apparent_JJ heightened_VBN GC_NNP response_NN in_IN 
        Lifr_NNP -_: /_NN -_: mice_NNS affects_VBZ both_DT sexes_NNS
        equally_RB ,_, it_PRP is_VBZ likely_JJ that_IN RU_NNP 486_CD attenuation_NN of_IN associated_VBN
        phenotypes_NNS is_VBZ primarily_RB mediated_JJ through_IN GR_NNP antagonism_NN ._.
        However_RB ,_, the_DT interconnectedness_NNS of_IN hormone_NN action_NN may_MD also_RB
        include_VB RU_NNP 486_CD mediated_JJ PR_NNP antagonism_NN as_IN a_DT means_NN of_IN
        impacting_VBG the_DT extent_NN of_IN GR-related_NNP effects_NNS ._.
        The_DT primary_JJ clinical_JJ utility_NN of_IN RU_NNP 486_CD is_VBZ PR_NNP antagonism_NN
        to_TO induce_VB early_JJ pregnancy_NN abortion_NN ._. Since_IN the_DT data_NNS were_VBD
        collected_VBN from_IN pups_NNS that_WDT were_VBD born_VBN early_RB by_IN natural_JJ
        delivery_NN (_( E_NNP 18_CD ._. 5_LS versus_CC E_NNP 19_CD ._. 5_LS -_: 21_CD ._. 5_LS )_) following_VBG RU_NNP 486_CD
        treatment_NN of_IN pregnant_JJ females_NNS ,_, it_PRP can_MD be_VB assumed_VBN that_IN the_DT
        RU_NNP 486_CD used_VBN was_VBD an_DT active_JJ PR_NNP antagonist_NN ,_, and_CC ,_, by_IN
        association_NN ,_, an_DT active_JJ GR_NNP antagonist_NN ._. The_DT effective_JJ dose_NN
        used_VBN in_IN this_DT study_NN was_VBD somewhere_RB between_IN 0_CD ._. 1_CD and_CC 0_CD ._. 2_CD
        Î¼g_NN /_NN gram_NN /_NN day_NN for_IN two_CD days_NNS ._. The_DT dose_NN was_VBD not_RB administered_VBN by_IN
        weight_NN since_IN litters_NNS vary_VBP in_IN size_NN and_CC will_MD have_VB a_DT large_JJ
        impact_NN on_IN maternal_NN weight_NN in_IN late_JJ gestation_NN ._. 0_CD ._. 3_CD
        Î¼g_NN /_NN gram_NN /_NN day_NN has_VBZ been_VBN reported_VBN to_TO induce_VB abortion_NN in_IN 5_CD %_NN of_IN
        mice_NNS during_IN early_JJ gestation_NN following_VBG 3_CD days_NNS of_IN
        administration_NN [_NN 59_CD ]_NN ._. The_DT dosage_NN used_VBN in_IN this_DT study_NN was_VBD
        able_JJ to_TO induce_VB pre-term_JJ birth_NN by_IN natural_JJ delivery_NN at_IN a_DT time_NN
        when_WRB the_DT pups_NNS were_VBD able_JJ to_TO survive_VB ex_FW utero_NN (_( E_NNP 18_CD ._. 5_LS )_) ,_, but_CC
        was_VBD well_RB below_IN the_DT dose_NN used_VBN to_TO achieve_VB clinical_JJ
        abortion_NN ._.
        The_DT apparent_JJ GC_NNP hyper-responsiveness_JJ in_IN LIFR_NNP null_NN pups_NNS
        is_VBZ probably_RB not_RB directly_RB due_JJ to_TO excess_JJ circulating_VBG
        corticosterone_NN in_IN the_DT absence_NN of_IN LIFR_NNP ._. Instead_RB ,_, expression_NN
        of_IN GR_NNP and_CC subsequent_JJ GR_NNP induced_VBD transcription_NN may_MD be_VB more_RBR
        relevant_JJ than_IN circulating_VBG GC_NNP level_NN ._. Another_DT consideration_NN
        is_VBZ that_IN the_DT benefit_NN of_IN RU_NNP 486_CD administration_NN may_MD be_VB either_CC
        central_JJ within_IN the_DT HPA_NNP or_CC can_MD be_VB due_JJ to_TO peripheral_JJ GR_NNP
        antagonism_NN ._. Cardiac_NNP dysfunction_NN has_VBZ not_RB yet_RB been_VBN explored_JJ
        in_IN the_DT LIFR_NNP null_NN model_NN ._. However_RB ,_, many_JJ of_IN the_DT defects_NNS caused_VBN
        by_IN gp_NN 130_CD loss_NN are_VBP shared_VBN by_IN mice_NNS with_IN a_DT null_NN mutation_NN of_IN
        LIFR_NNP ,_, reflecting_VBG the_DT heterodimeric_JJ relationship_NN of_IN LIFR_NNP and_CC
        gp_NN 130_CD for_IN functional_JJ LIFR_NNP :_: gp_NN 130_CD signaling_VBG ._. A_DT recent_JJ cardiac_JJ
        muscle_NN specific_JJ gp_NN 130_CD knockout_NN model_NN develops_VBZ normally_RB [_NN 60_CD
        ]_NN ._. Whereas_IN ,_, non-tissue_JJ specific_JJ gp_NN 130_CD knockout_NN results_NNS in_IN
        hypotrophic_JJ cardiac_JJ muscle_NN apparent_JJ by_IN E_NNP 15_CD ._. 5_LS [_NN 61_CD ]_NN ._. This_DT
        suggests_VBZ that_IN the_DT effect_NN of_IN gp_NN 130_CD knockout_NN on_IN cardiac_JJ
        development_NN is_VBZ mediated_JJ outside_IN of_IN cardiac_JJ tissue_NN and_CC the_DT
        primary_JJ developmental_NN defect_NN is_VBZ peripheral_JJ to_TO the_DT heart_NN ._.
        Given_VBN the_DT improvement_NN in_IN skeletal_NN muscle_NN noted_VBD in_IN this_DT
        study_NN following_VBG RU_NNP 486_CD ,_, it_PRP would_MD be_VB reasonable_JJ to_TO explore_VB a_DT
        central_JJ HPA_NNP defect_NN following_VBG gp_NN 130_CD loss_NN as_IN the_DT mediator_NN of_IN
        hypotrophic_JJ cardiac_JJ development_NN ._.
        Muscle_NNP regeneration_NN begins_VBZ through_IN the_DT muscle_NN precursor_NN
        satellite_NN cells_NNS ._. Activation_NNP is_VBZ followed_VBN by_IN proliferation_NN
        and_CC fusion_NN with_IN other_JJ satellite_NN cells_NNS to_TO form_VB new_JJ myotubes_NNS ._.
        Muscle_NNP regeneration_NN is_VBZ a_DT dynamic_JJ process_NN necessary_JJ in_IN the_DT
        maintenance_NN of_IN muscle_NN integrity_NN ._. LIF_NNP and_CC CNTF_NNP stimulate_VB
        muscle_NN regeneration_NN in_IN vivo_NN [_NN 62_CD 63_CD ]_NN ,_, as_IN do_VBP other_JJ growth_NN
        factors_NNS ;_: such_JJ as_IN insulin-like_JJ growth_NN factor_NN [_NN 64_CD 65_CD ]_NN ._. The_DT
        power_NN of_IN LIF_NNP to_TO regenerate_VB muscle_NN is_VBZ seen_VBN in_IN dystrophin_NN
        null_NN mdx_NN mice_NNS ,_, where_WRB exogenous_JJ LIF_NNP regenerates_NNS atrophied_JJ
        diaphragm_NN muscle_NN [_NN 66_CD ]_NN ._. LIF_NNP induced_VBD signaling_VBG appears_VBZ to_TO
        be_VB essential_JJ in_IN muscle_NN development_NN as_IN seen_VBN by_IN muscle_NN
        atrophy_NN in_IN the_DT absence_NN of_IN LIFR_NNP on_IN E_NNP 18_CD ._. 5_LS ._. In_IN the_DT absence_NN of_IN
        LIFR_NNP ,_, muscle_NN atrophy_NN may_MD be_VB caused_VBN by_IN GC_NNP induced_VBD alteration_NN
        of_IN metabolism_NN ,_, which_WDT leads_VBZ to_TO glycogen_NN accumulation_NN ,_,
        inhibition_NN of_IN protein_NN synthesis_NN and_CC stimulation_NN of_IN protein_NN
        degradation_NN [_NN 67_CD 68_CD ]_NN ._. Because_IN low_JJ levels_NNS of_IN RU_NNP 486_CD can_MD
        fully_RB protect_VB 
        Lifr_NNP -_: /_NN -_: fetal_JJ muscle_NN from_IN the_DT late_JJ
        gestation_NN GC_NNP surge_NN ,_, the_DT balance_NN between_IN hormone_NN function_NN
        and_CC muscle_NN integrity_NN appears_VBZ both_DT delicate_JJ and_CC direct_JJ ._.
        GR_NNP expression_NN is_VBZ specific_JJ but_CC widespread_JJ within_IN neuronal_NN
        and_CC glial_NN cell_NN populations_NNS ._. LIF_NNP is_VBZ also_RB responsible_JJ for_IN
        increased_VBN GFAP_NNP expression_NN [_NN 69_CD ]_NN ,_, while_IN signaling_VBG through_IN
        LIFR_NNP :_: gp_NN 130_CD is_VBZ critical_JJ in_IN fostering_VBG the_DT differentiation_NN of_IN
        neuronal_NN precursors_NNS into_IN astrocytes_NNS [_NN 70_CD ]_NN mediated_JJ through_IN
        STAT_NNP 3_CD [_NN 71_CD 72_CD 73_CD 74_CD ]_NN ._. Glial_NNP cells_NNS respond_VBP to_TO GC_NNP ,_, which_WDT ,_,
        in_IN turn_NN ,_, can_MD affect_VB transcriptional_NN control_NN of_IN GFAP_NNP level_NN
        either_CC positively_RB or_CC negatively_RB [_NN 74_CD ]_NN ._. The_DT present_JJ study_NN
        shows_VBZ that_IN GC_NNP 's_POS can_MD play_VB a_DT critical_JJ role_NN in_IN hindering_VBG
        astrocyte_NN development_NN in_IN the_DT absence_NN of_IN LIFR_NNP as_IN seen_VBN
        through_IN the_DT partial_JJ abrogation_NN of_IN this_DT defect_NN following_VBG
        exposure_NN to_TO RU_NNP 486_CD in_IN 
        Lifr_NNP -_: /_NN -_: mice_NNS ._. RU_NNP 486_CD crosses_VBZ the_DT
        blood-brain-barrier_JJ and_CC is_VBZ present_JJ at_IN only_RB 28_CD %_NN of_IN levels_NNS
        seen_VBN in_IN the_DT serum_NN [_NN 75_CD ]_NN ._. Perhaps_RB glial_NN development_NN would_MD
        be_VB further_RBR improved_VBN in_IN the_DT presence_NN of_IN higher_JJR levels_NNS of_IN
        RU_NNP 486_CD were_VBD these_DT levels_NNS not_RB abortive_JJ ._. The_DT RU_NNP 486_CD effect_NN is_VBZ
        not_RB likely_JJ to_TO be_VB mediated_JJ through_IN PR_NNP in_IN the_DT 
        Lifr_NNP -_: /_NN -_: astrocyte_NN precursors_NNS ,_, since_IN
        astrocytes_NNS have_VBP low_JJ levels_NNS of_IN PR_NNP 's_POS that_WDT are_VBP only_RB detectable_JJ
        in_IN females_NNS [_NN 76_CD ]_NN ._.
        The_DT vigor_NN displayed_VBN at_IN birth_NN by_IN RU_NNP 486_CD treated_VBN 
        Lifr_NNP -_: /_NN -_: pups_NNS is_VBZ striking_JJ and_CC
        suggests_VBZ sweeping_JJ improvement_NN in_IN well-being_NN ._. Pups_NNP of_IN all_DT 
        Lifr_NNP genotypes_NNS are_VBP able_JJ to_TO breathe_VB
        well_RB at_IN birth_NN and_CC 
        Lifr_NNP +_NN /_NN +_NN and_CC +_NN /_NN -_: pups_NNS thrive_VBP with_IN no_DT
        apparent_JJ lung_NN handicap_NN ._. This_DT indicates_VBZ that_IN the_DT improvement_NN
        due_JJ to_TO RU_NNP 486_CD is_VBZ implemented_VBN through_IN modest_JJ alteration_NN in_IN GC_NNP
        regulation_NN since_IN complete_JJ loss_NN of_IN GR_NNP function_NN leads_VBZ to_TO
        incomplete_JJ lung_NN development_NN at_IN birth_NN and_CC impaired_VBN survival_NN
        through_IN atelectasis_NNS [_NN 77_CD ]_NN ._. The_DT neural_NN compartment_NN may_MD
        have_VB been_VBN under-protected_JJ by_IN RU_NNP 486_CD due_JJ to_TO partial_JJ exclusion_NN
        by_IN the_DT blood-brain-barrier_JJ ,_, while_IN bone_NN and_CC skeletal_NN muscle_NN ,_,
        tissues_NNS exposed_VBN to_TO higher_JJR levels_NNS of_IN RU_NNP 486_CD ,_, were_VBD clearly_RB
        protected_VBN ._. Hypothalamus_NNP and_CC anterior_NN pituitary_JJ are_VBP also_RB
        protected_VBN by_IN the_DT blood-brain-barrier_JJ ._. Elevation_NNP of_IN ACTH_NNP in_IN
        response_NN to_TO RU_NNP 486_CD was_VBD apparent_JJ ._. Consequently_RB ,_, very_RB low_JJ
        levels_NNS of_IN RU_NNP 486_CD appear_VB to_TO mediate_VB partial_JJ neural_NN
        normalization_NN ._. Loss_NN of_IN neuronal_NN subpopulations_NNS integral_JJ to_TO
        suckling_VBG need_VBP to_TO be_VB explored_JJ in_IN the_DT RU_NNP 486_CD late_JJ gestation_NN
        pups_NNS ,_, but_CC the_DT data_NNS suggest_VBP that_IN the_DT health_NN of_IN this_DT
        population_NN is_VBZ not_RB directly_RB influenced_VBN by_IN altered_VBN GC_NNP
        response_NN ._.
      
      
        Conclusions_NNP
        In_IN conclusion_NN ,_, many_JJ of_IN the_DT multi-systemic_JJ defects_NNS during_IN
        late_JJ gestation_NN brought_VBN about_IN by_IN LIFR_NNP loss_NN were_VBD attenuated_JJ
        using_VBG maternal_NN RU_NNP 486_CD administration_NN ._. Osteopenia_NNP is_VBZ reduced_VBN ,_,
        muscle_NN integrity_NN is_VBZ normal_JJ and_CC glial_NN cells_NNS are_VBP forming_VBG ._. The_DT
        mother_NN can_MD no_RB longer_RB detect_VB abnormalities_NNS in_IN the_DT LIFR_NNP null_NN
        pups_NNS severe_JJ enough_RB to_TO stimulate_VB culling_VBG behavior_NN ._. However_RB ,_,
        motor_NN neuron_NN deficit_NN appears_VBZ functionally_RB unaffected_JJ and_CC
        the_DT newborn_JJ pups_NNS still_RB succumb_NN through_IN inability_NN to_TO suckle_NN ._.
        These_DT results_NNS indicate_VBP that_IN signaling_VBG through_IN LIFR_NNP
        utilizing_VBG the_DT LIFR_NNP :_: gp_NN 130_CD heterodimer_NN is_VBZ essential_JJ for_IN an_DT
        appropriate_JJ GC_NNP response_NN during_IN development_NN ._.
      
      
        Authors_NNP '_'' contributions_NNS
        CBW_NNP conceived_VBD of_IN the_DT study_NN and_CC participated_VBD in_IN all_DT
        aspects_NNS including_VBG coordination_NN ,_, mouse_NN husbandry_NN ,_, tissue_NN
        collection_NN ,_, genotyping_VBG ,_, histology_NN ,_, immunohistochemistry_NN and_CC
        data_NNS analysis_NN ._. AMN_NNP assisted_VBN with_IN mouse_NN husbandry_NN and_CC tissue_NN
        collection_NN ._. DL_NNP provided_VBD pathology_NN expertise_NN and_CC valued_VBN
        discussion_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ
        manuscript_NN ._.
      
    
  
